IOL Chemicals And Pharmaceuticals Ltd.

NSE: IOLCP BSE: 524164 SECTOR: Pharmaceuticals & Drugs  161k   2k   313

451.20
+4.75 (1.06%)
NSE: Today, 03:59 PM

Price Summary

Today's High

₹ 463.45

Today's Low

₹ 446.6

52 Week High

₹ 463.4

52 Week Low

₹ 272.8

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyExcellent
The company knows very well the utilization of its assets.
FinancialsAverage
The company could improve upon its asset employment.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

2648.79 Cr.

Enterprise Value

2553.66 Cr.

No. of Shares

5.87 Cr.

P/E

18.92

P/B

1.76

Face Value

₹ 10

Div. Yield

0.89 %

Book Value (TTM)

₹  256.63

CASH

137.88 Cr.

DEBT

42.75 Cr.

Promoter Holding

48.19 %

EPS (TTM)

₹  23.84

Sales Growth

11.03%

ROE

12.5 %

ROCE

17.16%

Profit Growth

-62.74 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year11.03%
3 Year9.02%
5 Year25.18%

Profit Growth

1 Year-62.74%
3 Year-11.21%
5 Year104.16%

ROE%

1 Year12.5%
3 Year37.5%
5 Year39.15%

ROCE %

1 Year17.16%
3 Year46.48%
5 Year42%

Debt/Equity

0.0307

Price to Cash Flow

29.09

Interest Cover Ratio

27.8805790108565

CFO/PAT (5 Yr. Avg.)

1.07977927195346

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2023 48.19 0
Dec 2022 43.69 0
Sep 2022 43.69 0
Jun 2022 43.69 0
Mar 2022 43.69 0
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company has been maintaining healthy ROE of 37.497809595254% over the past 3 years.
  • Company has been maintaining healthy ROCE of 46.4825812109114% over the past 3 years.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 27.8805790108565.
  • The Company has been maintaining an effective average operating margins of 21.6727632049095% in the last 5 years.
  • The company has an efficient Cash Conversion Cycle of 47.9514307040916 days.
  • The company has a good cash flow management; CFO/PAT stands at 1.07977927195346.

 Limitations

  • The company has shown a poor profit growth of -11.2149589759325% for the Past 3 years.
  • The company has shown a poor revenue growth of 9.02444549303834% for the Past 3 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023
Net Sales 572.49 565.01 541.41 523.48 587.21
Total Expenditure 529.37 508.99 509.74 480.44 491.42
Operating Profit 43.12 56.02 31.67 43.04 95.79
Other Income 6.93 5.15 5.06 6.64 8.72
Interest 2.34 3.38 3.51 4.7 4.88
Depreciation 11.01 10.98 11.32 11.73 12.1
Exceptional Items 0 0 0 0 0
Profit Before Tax 36.7 46.81 21.9 33.25 87.53
Tax 8.95 11.92 6.23 9.1 22.26
Profit After Tax 27.75 34.89 15.67 24.15 65.27
Adjusted EPS (Rs) 4.73 5.94 2.67 4.11 11.12

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Net Sales 983.3 1685.33 1894.47 1966.98 2184.02
Total Expenditure 863.77 1275.68 1320.59 1375.14 1927.74
Operating Profit 119.53 409.65 573.88 591.84 256.28
Other Income 6.33 10.37 16.02 24.3 32.04
Interest 64.35 51.42 20.93 5.83 8.29
Depreciation 30.21 32.45 35.73 38.92 43.26
Exceptional Items 0 0 0 0 -13.93
Profit Before Tax 31.3 336.15 533.24 571.39 222.84
Tax 3.6 99.45 171.95 126.83 57.18
Net Profit 27.7 236.7 361.29 444.56 165.66
Adjusted EPS (Rs.) 4.93 41.61 63.51 75.72 28.22

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Equity and Liabilities
Share Capital 56.21 56.89 56.89 58.71 58.71
Total Reserves 159.53 417.45 756.65 1201.72 1331.56
Borrowings 258.12 189.88 0 0 0
Other N/C liabilities 22.17 20.77 79.73 59.11 56.62
Current liabilities 350.97 324.79 453.63 432.8 575.29
Total Liabilities 847 1009.78 1346.9 1752.34 2022.18
Assets
Net Block 405.64 411.72 469.04 512.36 560.64
Capital WIP 6.95 27.02 19.19 48.27 102.03
Intangible WIP 0 0 0 0 3.17
Investments 0 0 0 0 0.1
Loans & Advances 1.26 11.56 1.33 17.61 10.77
Other N/C Assets 2.17 7.3 9.43 21.95 204.87
Current Assets 430.98 552.18 847.91 1152.15 1140.6
Total Assets 847 1009.78 1346.9 1752.34 2022.18
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Profit from operations 31.3 336.15 533.24 571.39 222.84
Adjustment 91.64 82.35 51.93 27.15 33.12
Changes in Assets & Liabilities 3.14 -77.64 2.78 -76.51 -102.34
Tax Paid -6.36 -67.69 -117.15 -142.25 -62.58
Operating Cash Flow 119.72 273.17 470.8 379.78 91.04
Investing Cash Flow -50.38 -63.04 -184.23 -317.25 -120.29
Financing Cash Flow -70.36 -197.46 -271.89 -58.28 -1.64
Net Cash Flow -1.02 12.67 14.68 4.25 -30.89

Corporate Actions

Investors Details

PARTICULARS Mar 2022% Jun 2022% Sep 2022% Dec 2022% Mar 2023%
Promoters 43.69 43.69 43.69 43.69 48.19
maya devi polycot ... 17.04 17.04 17.04 17.04 17.04
nm merchantiles li... 8.65 8.65 8.65 8.65 8.65
ncg enterprises li... 5.59 5.59 5.59 5.59 5.59
bhudeva lifescienc... 4.90 4.90 4.90 4.90 4.90
ncvi enterprises l... 4.79 4.79 4.79 4.79 4.79
varinder gupta 2.04 2.04 2.04 2.04 2.04
true value traders... 0.68 0.68 0.68 0.68 0.68
PARTICULARS Mar 2022% Jun 2022% Sep 2022% Dec 2022% Mar 2023%
Investors 56.31 56.31 56.31 56.31 51.81
vasudeva commercia... 7.94 7.94 7.94 7.94 7.94
trichit limited 4.50 4.50 4.50 4.50 4.50
vasudeva fuels pri... - - - - -
vasudeva organics ... - - - - -
enorg limited 4.43 4.43 4.43 4.43 4.43
g consultants and ... 1.68 1.68 1.68 1.68 1.68
ashish kacholia 1.97 1.97 1.97 1.97 1.97
morgan stanley asi... - - - - -
stichting deposita... - - - - -
pinebridge global ... 1.05 1.05 1.05 1.05 1.05
acadian emerging m... - - - - -

Annual Reports

Ratings & Research Reports

Company Presentations

Company News

IOL Chemicals & Pharmaceuticals informs about presentation 3 Jun 2023, 12:08PM IOL Chemicals and Pharmaceuticals informs about investor conference call8 May 2023, 4:51PM IOL Chemicals and Pharmaceuticals informs about press release8 May 2023, 2:11PM IOL Chemicals gets Certificate of Suitability to export Paracetamol in European market8 May 2023, 12:29PM Iol Chemicals & Pharmaceuticals informs about press release29 Apr 2023, 3:38PM Iol Chemicals & Pharmaceuticals informs about loss of share certificate29 Apr 2023, 3:16PM IOL Chemicals and Pharmaceuticals reports 2- fold jump in Q4 consolidated net profit28 Apr 2023, 4:15PM IOL Chemicals & Pharmaceuticals informs about outcome of board meeting28 Apr 2023, 3:20PM IOL Chem & Pharma - Quaterly Results28 Apr 2023, 1:54PM IOL Chem & Pharma - Quaterly Results28 Apr 2023, 1:54PM IOL Chem & Pharma - Quaterly Results28 Apr 2023, 1:54PM IOL Chemicals & Pharmaceuticals informs about clarification on price movement21 Apr 2023, 12:49PM IOL Chemicals & Pharmaceuticals informs about press release5 Apr 2023, 10:52AM Iol Chemicals & Pharmaceuticals informs about analyst meet10 Mar 2023, 12:37PM IOL Chemicals and Pharmaceuticals reports 40% fall in Q3 net profit8 Feb 2023, 2:07PM IOL Chem & Pharma - Quaterly Results7 Feb 2023, 5:49PM IOL Chem & Pharma - Quaterly Results7 Feb 2023, 5:49PM IOL Chem & Pharma - Quaterly Results7 Feb 2023, 5:49PM IOL Chemicals and Pharmaceuticals informs about board meeting 1 Feb 2023, 5:19PM IOL Chemicals and Pharmaceuticals incorporates wholly owned subsidiary in UK1 Feb 2023, 3:17PM IOL Chemicals and Pharmaceuticals informs about analyst meet 6 Dec 2022, 4:45PM IOL Chemicals and Pharmaceuticals receives patent from Government of India24 Nov 2022, 12:21PM IOL Chemicals and Pharmaceuticals informs about transcript of earnings call19 Nov 2022, 3:55PM IOL Chemicals and Pharmaceuticals gets nod to incorporate wholly owned subsidiary16 Nov 2022, 11:40AM IOL Chemicals and Pharmaceuticals reports 69% fall in Q2 consolidated net profit15 Nov 2022, 4:10PM IOL Chem & Pharma - Quaterly Results14 Nov 2022, 6:27PM IOL Chem & Pharma - Quaterly Results14 Nov 2022, 6:27PM IOL Chemicals gets CEP to supply Pantoprazole Sodium Sesquihydrate API in Europe8 Nov 2022, 11:01AM IOL Chemicals and Pharmaceuticals informs about disclosure 3 Nov 2022, 10:51AM IOL Chemicals and Pharmaceuticals informs about loss of share certificate13 Oct 2022, 5:05PM IOL Chemicals receives REACH certification for supply of ethyl acetate across European markets8 Oct 2022, 4:15PM IOL Chemicals and Pharmaceuticals gets nod to invest $2.1 million in USpharma23 Sep 2022, 11:38AM IOL Chemicals and Pharmaceuticals inks pact with Adfactors PR17 Sep 2022, 10:15AM IOL Chemicals and Pharmaceuticals informs about transcript of conference call16 Aug 2022, 4:39PM IOL Chem & Pharma - Quaterly Results9 Aug 2022, 8:06PM IOL Chem & Pharma - Quaterly Results9 Aug 2022, 8:06PM IOL Chemicals and Pharmaceuticals incorporates wholly owned subsidiary 29 Jun 2022, 9:10AM IOL Chemicals and Pharmaceuticals incorporates wholly owned subsidiary22 Jun 2022, 9:23AM IOL Chemicals And Pharmaceuticals informs about investors conference 15 Jun 2022, 10:17AM IOL Chem & Pharma - Quaterly Results30 May 2022, 8:55PM IOL Chem & Pharma - Quaterly Results30 May 2022, 8:55PM IOL Chemicals & Pharmaceuticals informs about loss of share certificates 28 Mar 2022, 1:57PM IOL Chemicals & Pharmaceuticals informs about details of loss of share certificate 26 Mar 2022, 12:19PM IOL Chemicals & Pharmaceuticals informs about voting result 19 Mar 2022, 4:21PM IOL Chemicals and Pharmaceuticals incorporates wholly owned subsidiary company 16 Mar 2022, 4:57PM IOL Chemicals And Pharmaceuticals informs about transcript of earnings call22 Feb 2022, 1:13PM IOL Chemicals and Pharmaceuticals informs about newspaper publication5 Feb 2022, 3:28PM IOL Chemicals and Pharmaceuticals reports 65% fall in Q3 net profit5 Feb 2022, 10:46AM IOL Chemicals And Pharmaceuticals informs about outcome of board meeting5 Feb 2022, 9:57AM IOL Chem & Pharma - Quaterly Results4 Feb 2022, 6:30PM

IOL Chem & Pharma Stock Price Analysis and Quick Research Report. Is IOL Chem & Pharma an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into IOL Chem & Pharma and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Its cash from the operating activity was Rs 91.04 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. IOL Chem & Pharma has a Debt to Equity ratio of 0.0307 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In IOL Chem & Pharma , the EPS growth was -62.7361125601383 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, IOL Chem & Pharma has OPM of 11.7343247772456 % which is a bad sign for profitability.
     
  • ROE: IOL Chem & Pharma have a average ROE of 12.4993397970347 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
Brief about IOL Chem & Pharma

X